Day: November 13, 2020

At an extraordinary general meeting on 13 November 2020 the following decision was made.Decision to approve the board of directors´ resolution on the rights issue of Class A and Class B ordinary sharesThe extraordinary general meeting approved the board of directors’ resolution dated 6 October 2020 regarding the new issue of Class A and B ordinary shares with preferential rights for the holders of ordinary shares. The new issue will entail issue proceeds of approximately SEK 2 billion, before any costs relating to the new issue. The purpose is to use the issue proceeds to continue to implement the company’s strategy by giving the company room for continued value creation through selective acquisitions to the Swedish or international property portfolio as well as project development of commercial and residential premises. In addition,...

Vid en extra bolagsstämma den 13 november 2020 fattades följande beslut.Beslut om godkännande av styrelsens beslut om företrädesemission av stamaktierserie A och BDen extra bolagsstämman godkände styrelsens beslut från den 6 oktober 2020 om nyemission av stamaktier av serie A och serie B med företrädesrätt för stamaktieägarna. Nyemissionen ska avse en emissionslikvid om cirka 2 miljarder kronor, före emissionskostnader. Syftet är att använda emissionslikviden för att fortsatt verkställa bolagets strategi genom att ge bolaget utrymme för fortsatt värdeskapande genom selektiva förvärv till den svenska eller utländska fastighetsportföljen samt projektutveckling av kommersiella lokaler och bostäder. Därutöver kommer emissionslikviden ge bolaget en stärkt balansräkning, lägre belåningsgrad och ökad finansiell flexibilitet.Klövern är ett fastighetsbolag...

VANCOUVER, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) — SouthGobi Resources Ltd. (TSX: SGQ, HK: 1878) (“SouthGobi” or the “Company”) announces that Mr. Xiaoxiao Li (“Mr. Li”) has tendered his resignation as a non-executive director of the Company with effect from November 13, 2020.Mr. Li’s resignation as a director of the Company is a result of his recent departure from a subsidiary of a major shareholder of the Company which had nominated Mr. Li to serve as a director of the Company.Mr. Li has confirmed that he has no disagreement with the board of directors of the Company (the “Board”) and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company.The Board takes this opportunity to express its very sincere gratitude to Mr. Li for his valuable contribution...

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — Staffing 360 Solutions, Inc. (NASDAQ: STAF), a company executing an international buy-integrate-build strategy through the acquisition of staffing organizations in the United States and the United Kingdom, today announced that it has received written notice from the Nasdaq Stock Market Listing Qualifications Staff on November 12, 2020, indicating that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq Capital Markets Listing rule 5550(a)(2). Nasdaq considers the matter closed.Brendan Flood, Chairman and Chief Executive Officer, said, “With this matter now resolved, and the previously announced recent successful restructuring of our senior debt, we continue our laser focus on driving growth and creating shareholder value.”About Staffing 360...

CARB-X and Cystic Fibrosis Foundation grants provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infectionsInitiated expanded access program with exebacase for the treatment of persistent MRSA bloodstream infections in COVID-19 patientsYONKERS, New York, Nov. 13, 2020 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the third quarter ended September 30, 2020.“We are pleased with the progress of the Phase 3 DISRUPT superiority study of exebacase, which received Breakthrough Therapy designation...

SÃO PAULO, Brazil, Nov. 13, 2020 (GLOBE NEWSWIRE) — Vasta Platform Limited (NASDAQ: VSTA) – “Vasta” or the “Company,” announces today its financial and operating results for the third quarter of 2020 (3Q20) ended September 30, 2020. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS).HIGHLIGHTSWith the completion of the 2020 sales cycle (4Q19 to 3Q20), Vasta reported a subscription revenue of R$692 million, which represents 18% increase in comparison to the subscription revenue for the 2019 sales cycle (R$584 million), or 21% higher than the ACV 2019 (R$572 million), and reinforces the resilience of our business by showing a solid result even during a period of strong socioeconomic instability caused by the pandemic.The subscription revenue for...

CHICAGO, Nov. 13, 2020 (GLOBE NEWSWIRE) — Professional Diversity Network, Inc. (NASDAQ:IPDN), (“IPDN” or the “Company”), a global developer and operator of online and in-person networks that provide access to networking, training, educational and employment opportunities for diverse individuals, today announced its financial results for the three and nine months ended September 30, 2020.Third Quarter Financial Highlights:Total Company revenues increased by $354,000 or 37.2%, from $952,000 during the three months ended June 30, 2020, to $1,306,000 for the three months ended September 30, 2020.PDN Network revenues increased by $389,000 or 65.1% compared to the revenues for the second quarter of 2020. The significant increase in revenues was attributable to higher customer acquisitions and continued growth in our recruitment business...

Valoe Corporation                           Stock Exchange Release 13 November 2020 at 15.15 Finnish timeISSUE OF CONVERTIBLE NOTES AND WARRANTS AND CONVERSION OF CONVERTIBLE NOTES PURSUANT TO FINANCING ARRANGEMENT BETWEEN VALOE CORPORATION AND WINANCEValoe Corporation (“Valoe” or the “Company”) has, pursuant to the terms and conditions of the financing arrangement between Valoe Corporation and Winance announced on 22 April 2020, withdrawn a total of EUR 200,000 of the third convertible notes tranche and issued to Winance in total 200 convertible notes and in total 800,000 warrants related thereto.Further, the Board of Directors of Valoe has, pursuant to the terms and conditions of the financing arrangement between Valoe Corporation and Winance announced on 22 April 2020, resolved to approve the request of Winance to convert...

Valoe Oyj                                      Pörssitiedote 13.11.2020 klo 15.15VALOE OYJ:N JA WINANCEN VÄLISEN RAHOITUSJÄRJESTELYN MUKAISTEN VAIHTOVELKAKIRJALAINOJEN JA WARRANTTIEN LIIKKEESEENLASKU JA VAIHTOVELKAKIRJALAINOJEN VAIHTAMINEN OSAKKEIKSIValoe Oyj (”Valoe” tai “Yhtiö”) on 22.4.2020 julkistetun Yhtiön ja Winance Investmentin (”Winance”) välisen rahoitusjärjestelyn (”Rahoitusjärjestely”) ehtojen mukaisesti nostanut 200.000 euroa Rahoitusjärjestelyn mukaisesta kolmannesta Lainaerästä sekä antanut Winancelle siihen liittyen yhteensä 200 vaihtovelkakirjaa ja 800.000 warranttia.Lisäksi Valoen hallitus on 22.4.2020 julkistetun Yhtiön ja Winancen välisen rahoitusjärjestelyn ehtojen mukaisesti päättänyt hyväksyä Winacen pyynnön vaihtaa 50.000 euron vaihtovelkakirjalainaosuus Yhtiön osakkeiksi merkintähinnalla 0,04 euroa...

Additional data from SIGNAL Huntington’s disease (HD) trial support continued development in HD and in Alzheimer’s disease (AD)Phase 1/2 Study to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for H1 2021Ended the quarter with cash and cash equivalents of $17.1 millionROCHESTER, N.Y., Nov. 13, 2020 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company developing innovative therapies for the treatment of neurodegenerative diseases and cancer, and supporting multiple collaborations with large biotech and major pharma partners through a proprietary discovery platform that enables selection of high value antibodies to difficult multipass membrane receptors, today announced financial results for the third quarter ended...